Fedratinib in Combination With Nivolumab
Key claim: A phase II trial is investigating whether combining fedratinib with nivolumab can achieve clinical efficacy in myelofibrosis patients who are resistant to or have had a suboptimal response to prior JAK inhibitor therapy.
Abstract
A multicenter, open-label, single arm, phase II study investigating the clinical efficacy of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment
Why this matters
JAK-inhibitor-resistant or suboptimally responding myelofibrosis remains a high-unmet-need PMF subpopulation, and most combination strategies to date have layered targeted agents (BET, LSD1, PI3K, XPO1, ERK) onto JAK inhibition. Pairing fedratinib with nivolumab introduces PD-1 immune checkpoint blockade as a mechanistically distinct partner, testing whether immune reactivation can augment JAK inhibition in a disease where checkpoint inhibitors have not yet established a role. A positive signal would open a new therapeutic axis specifically for the JAKi-refractory PMF natural history.